ArticleJAC-antimicrobial resistance2022
Evolution of cefiderocol resistance in
Article in JAC-antimicrobial resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Article
- Acquired resistance in Stenotrophomonas maltophilia: Mechanisms underlying the shift from multidrug to pandrug resistance.European journal of microbiology & immunology · 2026Review
- Ferrichrome: bacterial function, synthetic mimics, and biomedical applications.Frontiers in microbiology · 2026Review
- Antimicrobial resistance mechanisms, treatment challenges, and emerging strategies inFrontiers in cellular and infection microbiology · 2026Review
- Draft genome sequence ofMicrobiology resource announcements · 2025Article
- Repurposing the Anticancer Drug KP46 to Beat the CRAB out of Resistance: Towards an Orally Active Ga-Based Antiplantonic and Antibiofilm Agent.Antibiotics (Basel, Switzerland) · 2025Article
- Genomic and machine learning approaches to predict antimicrobial resistance inMicrobiology spectrum · 2025Article
- Clinical Outcomes of Eravacycline in Patients Treated for Stenotrophomonas maltophilia Infections.Infectious diseases and therapy · 2025Article
- Cefiderocol-ResistantCase reports in infectious diseases · 2025Article
- Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol.Current issues in molecular biology · 2024Review
- In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol.The Journal of antibiotics · 2024Article
- Efflux pump-mediated resistance to new beta lactam antibiotics in multidrug-resistant gram-negative bacteria.Communications medicine · 2024Review
- In Vitro Resistance-Predicting Studies and In Vitro Resistance-Related Parameters-A Hit-to-Lead Perspective.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Clinical and in vitro models identify distinct adaptations enhancing Staphylococcus aureus pathogenesis in human macrophages.PLoS pathogens · 2024Article
- Review
- Article
- An Overview of Cefiderocol's Therapeutic Potential and Underlying Resistance Mechanisms.Life (Basel, Switzerland) · 2023Review
- Cefiderocol Treatment for Severe Infections due to Difficult-to-Treat-Resistant Non-Fermentative Gram-Negative Bacilli in ICU Patients: A Case Series and Narrative Literature Review.Antibiotics (Basel, Switzerland) · 2023Review
- Article
- Clinical challenges treatingJAC-antimicrobial resistance · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCefiderocol is a siderophore cephalosporin active against MDR Gram-negatives including
methodsWe selected cefiderocol resistance in three clinical strains of
resultsEach parent strain was initially susceptible to cefiderocol (MICs of 0.03125, 0.03125 and 0.125 mg/L), and one initially tested susceptible to ceftazidime/avibactam (MIC 4 mg/L). We recovered evolved isolates achieving cefiderocol resistance at MICs of 8-32 mg/L from each parental strain. Some cefiderocol resistant isolates reverted following one to four drug-free passages. Ceftazidime/avibactam MICs of passaged isolates repeatedly increased to ≥256 mg/L, and while other MICs were largely unchanged, trimethoprim/sulfamethoxazole MICs declined 4-fold in two strains. WGS revealed one evolved isolate carrying six coding mutations, while four were isogenic mutants of
conclusions
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.